This is the target market for Ryoncil. Meso’s second product is Revascor (rexlemestrocel-L), which, as I noted many times before, was something of a trouble for the company, having failed ...
Teva Pharmaceutical Industries Ltd. ADR 4.58% $23.57B ...
AVXL Anavex Life Sciences Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback